Mometasone ointment steroid class

Ninety-seven pediatric subjects ages 6 to 23 months with atopic dermatitis were enrolled in an open-label HPA axis safety study. ELOCON Cream was applied once daily for approximately 3 weeks over a mean body surface area of 41% (range 15%-94%). In approximately 16% of subjects who showed normal adrenal function by Cortrosyn test before starting treatment, adrenal suppression was observed at the end of treatment with ELOCON Cream. The criteria for suppression were: basal cortisol level of ≤ 5 mcg/dL, 30-minute post-stimulation level of ≤ 18 mcg/dL, or an increase of < 7 mcg/dL. Follow-up testing 2 to 4 weeks after stopping treatment, available for 5 of the subjects, demonstrated suppressed HPA axis function in one subject, using these same criteria [see Use in Specific Populations ].

During pregnancy and lactation treatment with Mometasone Furoate should be performed only on the physician's order. Then however, the application on large body surface areas or over a prolonged period should be avoided. There is inadequate evidence of safety in human pregnancy. Topical administration of corticosteroids to pregnant animals can cause abnormalities of fetal development including cleft palate and intra-uterine growth retardation. There are no adequate and well-controlled studies with Mometasone Furoate in pregnant women and therefore the risk of such effects to the human fetus is unknown. However as with all topically applied glucocorticoids, the possibility that fetal growth may be affected by glucocorticoid passage through the placental barrier should be considered. There may therefore be a very small risk of such effects in the human fetus. Like other topically applied glucocorticoids, Mometasone Furoate should be used in pregnant women only if the potential benefit justifies the potential risk to the mother or the fetus.

Like other topical corticosteroids, mometasone furoate has antiinflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the antiinflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A 2 .

Instruct patient or caregiver on the proper use of the nasal spray.
Shake well before each use.
Before using for the first time, the unit must be primed. Keep the sprayer pointed away from people and pets. Pump the activator 10 times or until a fine spray appears. If the unit has not been used for 1 week, re-prime by pumping the activator twice or until a fine spray appears.
After administration, wipe the nasal applicator with a clean tissue. Replace the cap right after cleaning.
To avoid the spread of infection, do not use the inhaler in more than one person.

Mometasone ointment steroid class

mometasone ointment steroid class

Instruct patient or caregiver on the proper use of the nasal spray.
Shake well before each use.
Before using for the first time, the unit must be primed. Keep the sprayer pointed away from people and pets. Pump the activator 10 times or until a fine spray appears. If the unit has not been used for 1 week, re-prime by pumping the activator twice or until a fine spray appears.
After administration, wipe the nasal applicator with a clean tissue. Replace the cap right after cleaning.
To avoid the spread of infection, do not use the inhaler in more than one person.

Media:

mometasone ointment steroid classmometasone ointment steroid classmometasone ointment steroid classmometasone ointment steroid classmometasone ointment steroid class

http://buy-steroids.org